AbbVie (ABBV) announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular lymphoma (FL). The drug has been developed in partnership with Genmab (GMAB) .The FDA approved Epkinlyunder the accelerated pathway to treat adults with relapsed or refractory (R/R) FL after two or more lines of therapies. The agency initially granted accelerated approval to the drug last year to treat patients with R/R diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphom ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned +10.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 5.2% over this period. Now the key question is: Where could the stock be headed in the near term?Although ...

Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD)NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibod ...

Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and Products, Increasing Affordability of Treatments with Flexible Payment Options IRVINE, Calif., June 27, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today debuted Allē Payment Plans, powered by Cherry. By giving consumers the power to pay over-time for aesthetic treatments and pr ...

Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover, develop and commercialize new medicines targeting novel G protein-coupled receptor (GPCR) targets assoc ...

-  EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL)-  Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system-  FL is considered incurable with current standard of care therapies. Many people living with FL who have relapsed or are refractory to existing therapies have limited treatment options and reduced survival1NORTH CHICAGO, ...

AbbVie (ABBV) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for ABBV-951 for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). This is the second CRL issued for ABBV-951 by the FDA.The latest CRL was based on some observations on inspection of one of AbbVie's third-party manufacturing facilities listed in the NDA. The inspection did not involve ABBV-951 or any other AbbVie drug. The FDA has not requ ...

The most recent trading session ended with AbbVie (ABBV) standing at $170.75, reflecting a -1.15% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.09%. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, added 0.16%.Heading into today, shares of the drugmaker had gained 9.98% over the past month, outpacing the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.Investors will be eagerly watching for the per ...

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufacturing facilitiesThe CRL does not identify any issues related to the safety, efficacy or labeling of ABBV-951, including the device, and does not request that AbbVie conduct additional efficacy or safety trials related to the drug or device-related testingAbbVie continues to work with the FDA to bring ABBV-951 ...

Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true.If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (ABBV 1.38%), Ares Capital (ARCC 0.44%), and Realty Income (O 0.92%) have what it takes to deliver heaps of dividend payments to your portfolio in the years ahead.Whether you're interested in a high yield up front, rapid payout growth, or a litt ...